Skip to main content
OpenTrials
Completed

NCT Number: NCT04526457

Is Family Screening Improved by Genetic Testing of Familial Hypercholesterolemia

To test the hypothesis that in patients with a clinical diagnosis of familial hypercholesterolemia (FH), genetic testing and identification of a causative mutation might enhance the success of family-based cascade screening.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypercholesterolemia, Familial Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dyslipidemias Genetic Diseases, Inborn Hyperlipidemias Hyperlipoproteinemia Type II Hyperlipoproteinemias Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Metabolic Diseases Metabolism, Inborn Errors Nutritional and Metabolic Diseases

Age range

10 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

To examine the impact of genetic testing on the efficiency of cascade screening for FH, patients with suspected FH or a clinical diagnosis of FH have been randomized to genetic testing or standard of care with lipid testing alone. After systematic encouragement of family enrollment, as a primary endpoint, the compared the number of probands with relatives enrolled in each group one year after results were returned to probands. The secondary endpoints examined include the number of relatives enrolled within 52 weeks of the genetic counseling call and the number of relatives diagnosed with FH through the study. Exploratory subgroup analyses were conducted stratifying the cohort by randomization/genetic test result. Further exploratory analyses compared probands' perceptions about high cholesterol diagnosis at baseline and at 20 weeks from enrollment

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For probands, inclusion criteria are as follows:
  • LDL cholesterol > 220 mg/dL or a previous clinical diagnosis of FH
  • Aged 18 years or older
  • Ability to provide informed consent
  • Willingness/ability to contact a minimum of 2 biological relatives about the study

Exclusion criteria

  • For family members of probands, inclusion criteria are as follows:
  • Willingness to participate in the study
  • Age 10 or older
  • Ability to give informed consent/assent

Treatment and study plan

Standard of care

Other

Randomized to standard of care with lipid testing only.

Genetic Testing

Other

Randomized to genetic testing.

Primary outcomes

  1. Number of probands with relatives enrolled

    Time frame: 52 weeks after genetic/lipid testing results are returned to probands

    The primary outcome of this study was the number of probands with family members enrolled in the study within 52 weeks of results being returned to probands. Investigators compared the proportion of probands with a relative enrolled in the genetic testing group with the proportion of probands with a relative enrolled in the usual care group (lipid testing only). Relative enrolment was defined as the return of a test kit within the study time frame.

Secondary outcomes

  1. The number of relatives enrolled in the study 52 weeks after results were returned to probands

    Time frame: 52 weeks after results are returned to probands

    The number of relatives enrolled in the study within 52 weeks of results being returned to probands. Investigators compared the number of relatives enrolled in the genetic testing group with the number of relatives enrolled in the usual care group (lipid testing only). Relative enrolment was defined as the return of a test kit within the study time frame.

  2. The number of family members diagnosed with FH 52 weeks after results were returned to probands

    Time frame: 52 weeks after results are returned to probands

    The number of family members diagnosed with FH within 52 weeks of results being returned to probands. Investigators compared the number of enrolled relatives diagnosed with FH in the genetic testing group with the number of enrolled relatives diagnosed with FH in the usual care group (lipid testing only). This diagnosis had to be made through the study. The number of enrolled relatives diagnosed with FH in each group was expressed as the new case per index case ratio (relatives diagnosed with FH/total number of index case). Relative enrolment was defined as the return of a test kit within the study time frame. The diagnosis of FH was based on meeting either genetic or the Make Early Diagnosis To Prevent Early Deaths (MEDPED) clinical criteria

Other outcomes

  1. Proband perceptions about their high cholesterol including its etiology, management and heritability at 20 weeks after enrollment compared to baseline

    Time frame: 20 weeks after enrollment

    Proband perceptions about their high cholesterol including its etiology, management and heritability were examined at baseline and 20 weeks after enrollment, using a questionnaire administered at these time points. Investigators examined proband agreement/disagreement with statements about the etiology of their high cholesterol, its management and heritability in these questionnaires. Using this approach, investigators were able to determine the proportion of probands that agreed/disagreed with these statements, and could compare how these proportions differed between the groups of interest at baseline/follow-up and how these changed from baseline to follow-up.

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Acronym: IFIGhTFH

Important dates

Study start
2014
Primary completion
2016
Study completion
2017
First posted
Aug 25, 2020
Registry last updated
Dec 10, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.